International Journal of Immunology is a peer-reviewed open access journal that publishes original research articles as well as review articles in all areas of immunology. Immunology is a diverse and growing discipline that can be defined as the study of the tissues, cells and molecules involved in host defense mechanisms. Immunologists attempt to understand how the immune system develops, how the body defends itself against disease, and what happens when it all goes wrong. Priority is given to work that provides fundamental insight into the workings of the immune system. Areas covered include, but are not limited to, innate immunity and inflammation; development; immune receptors, signaling and apoptosis; antigen presentation; gene regulation and recombination; cellular and systemic immunity; vaccines; immune tolerance; autoimmunity and tumor immunology, microbial immunopathology; and transplantation.
The great advances in immunology in recent years make this field one of the most dynamic and rapidly growing in biological sciences. This remarkable growth is stimulated by the influx of investigators from other disciplines such as biochemistry, genetics, molecular biology, microbiology, virology and various medical disciplines. These disciplines are so well interlinked with immunology that no immunological challenge can now be properly addressed without sophisticated applications of expertise of combinations of these disciplines. As a consequence, immunology has become a vast and rich field encompassing discoveries and outlooks that range from the highly clinical to the highly molecular. Although such perspectives may appear diverse, they are, in fact, extremely interdependent. The journal seeks to present a balanced overview of contemporary immunology and melds together different aspects of molecular immunology, immunobiology and clinical immunology.
Immunology is the branch of biomedical science that deals with the response of an organism to antigenic challenge and its recognition of what is self and what is not. It deals with the defense mechanisms including all physical, chemical and biological properties of the organism that help it to combat its susceptibility to foreign organisms, material, etc
Immunology has its origins in the study of how the body protects itself against infectious diseases caused by microorganisms, such as bacteria, viruses, protozoa, and fungi, and also parasitic organisms, such as helminth worms. Research / review articles deals with, among other things, the physiological functioning of the immune system in states of both health and disease; malfunctions of the immune system in immunological disorders (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection); the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.
We take great pleasure in welcoming you to our new journal, International Journal of Immunology. We have created this publication with the intention of providing a space for the generation of knowledge, dialogue, critique, debate, and collaboration among an international community of immunologists, pathologists, researchers, scholars, etc.
Our vision is to create a high-quality publication that will be relevant, challenging, thought-provoking, for graduate students, academic researchers and scholars. We welcome original research papers, reviews articles, case studies, book reviews, and works-in progress.
We look forward to welcoming your submissions.
1. Adaptive immunity 11. Cancer and Tumor Immunobiology
2. Immunologic Techniques 12. Cellular & Regional Immunology
3. Transplantation Immunology 13. Combining Cancer Immunotherapies
4. Computational Immunology 14. Allergy prevention and risk factors
5. Immunology 15. Nutritional Immunology
6. Immunotherapy 16. Clinical Immunology
7. Pediatric Immunology 17. Reproductive Immunology
8. Immune Tolerance 18. Fungal Immunology
9. Mucosal Immunology 19. Neuro Immunology
10. Immune Toxicology 20.Immunoinformatics and System
Immune Scientific Networks:
Immunology Leadership & Committees consider proposals for Special Issues Editors will return a decision on your proposal within Two weeks of receipt. To enrich our vision of making the scientific information available at an ease of access, Immunology Leadership & Committees initiated special issue for the open access journals. All the articles published under a special issue focuses on a single topic providing the complete information about the ongoing research providing more insight on an emphasized topic of research enabling the readers access wide forecasted information on a particular topic Issue.
Special Issue Proposals: Special Issue deals with focused research topics of high interest, falling under the scope of the Journal. Special Issues are the pool of articles under a current topic selected from the Ongoing Research under specific discipline. The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in particular areas of research. These articles will provide an opportunity to the readers to understand and access the scientific information.
We encourage potential scientists to organize the Special Issue in their field of interests that fits within the Journal scope. This will provide an opportunity to increase the visibility of the Guest Editors. The Special Issue Titles may be from any basic and clinical area of Science, Technology and Medicine. People interested in publishing a special issue are advised to consider the following guidelines.
Your proposal should contain:
By submitting a Special Issue proposal to Immunology Leadership & Committees, you agree to abide by the Special Issue Editor Protocol should your proposal be accepted
Special issue articles are published immediately upon their acceptance and are released under upcoming regular issues. Special Issues are invited throughout the year. For more information or any queries about the special issues, please write us to firstname.lastname@example.org or email@example.com
Promoting Your Special Issue
Immunology Leadership & Committees will work with Guest Editors to increase the visibility of the Special Issue in the months leading up to the submission deadline and once it has been published.
What Immunology Leadership & Committees will do:
1. Immunology Leadership & Committees will circulate your Call for Papers to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs. It will also advertise your Call on the Immune websites and other social media platforms. It will re-issue the Call at appropriate intervals.
2. Once the Special Issue is published, announcements will be made to the Immune Editorial Board, targeted mailing lists, and relevant AoM listservs as well as on the Immune websites social media platforms.
3. Free access to the Special Issue will be made available in the website to Guest Editors and readers.
What is expected of Guest Editors?
1. We expect that Guest Editors will circulate the Call for Papers within their own personal networks, social media groups, and at any relevant conferences or workshops they may attend.
2. If it has not already been suggested as part of the proposal, consideration should be given to organizing a conference or workshop either to generate submissions or to aid in the development of submitted papers. A symposium or PDW at a well-known conference may also be considered.
3. We expect Guest Editors to identify up to 50 scholars for whom the Special Issue will be particularly relevant
If you have any queries, please contact Elena Griffin (firstname.lastname@example.org)
Honors & Awards:
1. Editorial Board Member of Journal of Hematology and Oncology Research Since Dec 2017.
2. Editorial Board Member of EMS Journal of Immunology&Allergy Since Aug 2017.
3. Editorial Board Member of SM Journal of Hematology & Multiple Myeloma Since Aug 2017.
4. Editorial Board Member of Journal of Immune Disorders & Therapy Since July 2017.
5. Editorial Board Member of Journal of Immunology Forecast Since July 2017.
6. Editorial Board Member of SM Neurodegenerative Disorders Since July 2017.
7. Editorial Board Member of SRL Multiple Sclerosis Since May 2017.
8. Editorial Board Member of International Journal of Clinical Oncology & Cancer Research Since April 2017.
9. Editorial Board Member of International Journal of Multiple Sclerosis and Related Disorders Since April 2017.
10. Editorial Board Member of Annals of Multiple Sclerosis and Related Disorders.Since Mar 2017.
11. Editorial Board Member of Allergy & Immunology Case Reports Since Mar 2017.
12. Editorial Board Member of Annals of Clinical and Experimental Immunology Since Mar 2017.
13. Editorial Board Member of SM Journal of Autoimmune Diseases Since Mar 2017.
14. Editorial Board Member of Insights in Pediatric Reseach Since Dec 2016.
15. Editorial Board Member of Journal of Immunology Research and Clinical Applications (JIRCA) Since Sep2016.
16. Editorial Board Member of Journal of Immunological Diseases, Disorders and their Prevention (AJIV) Since June 2016.
17. Editorial Board Member of ARC Journals of Immunology and Vaccines (AJIV). Since Nov 2015.
18. Iranian Authors, Journalist and Artists Support Credit Fund. Ministry of Ershad-e Eslami. Iran, Since 2006.
19. European Academy of Allergology & Clinical Immunology (EAACI). Sweden, 2006 -11.
20. Member of editorial board and incharge of medical news section in Journal of Ketab-e Hayyan. 2003-2004. Tehran, Iran.
21. Member of executive committee in Iranian Journal of Allergy, Asthma & Immunology, 2002-2004. Tehran, Iran.
22. Iranian society of Asthma & Allergy (ISAA). Iran, 2002-4.
23. Member of Organizing Committee of the 6th International Congress of Immunology and Allergy 2002, Tehran, Iran.
24. Member of Organizing Committee in 34th Congress of Moslem Physicians of North America 2001 in Radio & Television Exhibition Center. Tehran, Iran.
25. Iranian society for Immunology & Allergy (ISIA). Iran, Since 2000.
1. “IMMUNOCHEMISTRY: A BASIC AND PRACTICAL GUIDEBOOK” (Original). Jamee Negar Pub. 2015.
2. “EXPERIMENTAL METHODS IN IMMUNOLOGY”(Original). Jamee Negar Pub. 2014.
3. “CELLULAR AND MOLECULAR IMMUNOLOGY”. Abul K. Abbas, et al. 7th edition. (Translation).Hayyan Pub. 2012.
4. “AN OVERVIEW ON ORGANIZATION AND FUNCTION OF IMMUNE SYSTEM” (Original). Arad Ketab Pub. 2010
5. "A SUMMARY OF CELLULAR AND MOLECULAR IMMUNOLOGY"(Original). Hayyan Pub. 2008
6. “BASIC IMMUNOLOGY”. Abul K. Abbas, et al. 3nd edition. (Translation).Hayyan Pub. 2008
7. "ALLERGY”. Nelson. 18th edition. (Translation).Hayyan Pub. 2008
8. "RHEUMATOLOGIC DISORDERS”. Nelson. 18th edition. (Translation). Hayyan Pub. 2008
9. “IMMUNOLOGY" Nelson. 18th edition. (Translation). Hayyan Pub. 2008
10. “CELLULAR AND MOLECULAR IMMUNOLOGY”. Abul K. Abbas, et al. 6th edition. (Translation).Hayyan Pub. 2007.
11. “BASIC IMMUNOLOGY”. Abul K. Abbas, et al. 2nd edition.(Translation). Hayyan Pub. 2004.
12. “IMMUNOLOGY, ALLERGY AND RHEUMATOLOGY”. Nelson. 17th edition.(Translation). Hayyan Pub. 2004.
13. “CELLULAR AND MOLECULAR IMMUNOLOGY”. Abul K. Abbas,et al. 5th edition. (Translation). Hayyan Pub. 2003.
14. “IMMUNOLOGY A SHORT COURSE”. Eli Benjamin, et al.(Translation). Rastan Pub. 2001.
15. “MEDICAL IMMUNOLOGY”. Daniel P Stites, et al. 10th edition.(Translation). Rastan Pub. 2001.
16. “IMMUNE SYSTEM”. Peter Parham. 1st edition. (Translation). Vefagh Pub. 2000 .
1. Yazdani R, Shapoori S, Rezaeepoor M, Sanaei R, Ganjalikhani-Hakemi M, Azizi G, et al. Features and Roles of T Helper 9 Cells and Interleukin 9 in Immunological Diseases. Allergologia et Immunopathologia. Accepted in Feb 2018
2. Mohammad-Ganji M, Ganjalikhani-Hakemi M, Homayouni V, Rezaei A, Khanahmad H. Silencing of TIM-3 Expression by miR-326 Affects Apoptosis and Proliferation of Human HL-60 Leukemia Cell Line.International Journal of Hematology and Oncology. Accepted in Feb 2018.
3. Ghadiri N, Emamnia N, Ganjalikhani-Hakemi M, Ghaedi K, Etemadifar M, Salehi M, et al. Analysis of the expression of mir-34a,mir-199a, mir-30c and mir-19a in peripheral blood CD4+T lymphocytes of relapsing-remitting multiple sclerosis patients. Gene. Accepted In Feb 2018.
4. Shapoori S, Ganjalikhani-hakemi M, Rezaeepoor M, Alsahebfosoul F,Khosravi S, Etemadifar M, et al. Negative Regulation of Semaphorin 3A Expression in Peripheral Blood Mononuclear Cells Using MicroRNA-497-5p. Iranian Journal of Medical Sciences Accepted in Feb 2018.
5. Esmaeil N, Meratian N, Rezaei A, Mehrabian F, Ganjalikhani-Hakemi M, Homayouni V. A simple and cost benefit method for monocyte isolation. Razi Journal of Medical Sciences. Accepted in Jan 2018.
6. Cheraghi-pour K, Shariati L, Khanahmad H, Ganjalikhani hakemi M, Mirian M, Moridnia A, et al. effect sodium azide in inducement of apoptosis on hela cell infected by T. gondii. international journal of advanced biotechnology. Accepted in Nov 2017.
7. Cheraghi-pour K, Mohaghegh Ma, Moridnia A, Khanahmad H, Ganjalikhani hakemi M, Morad-pour K, et al. review of live attenuated vaccine in Toxoplasma gondii. International journal of advanced biotechnology. Accepted in Nov 2017.
8. Rezaeepoor M, Ganjalikhani-Hakemi M, Shapoori S, Eskandari N, Sharifi M, Etemadifar M, Mansourian M. Semaphorin-3A as an Immune Modulator is Suppressed by MicroRNA-145. Cell Journal 2018;20(1):113-9.
9. Yazdani R, Seify R, Ganjalikhani-Hakemi M, Abolhassani H, Eskandari N, Golsaz-Shirazi F, et al. Comparison of various classifications for patients with common variable immunodeficiency (CVID) using measurement of B-cell subsets. Allergologia et Immunopathologia. 2017;45(2):183-92.
10. Yazdani R, Ganjalikhani-Hakemi M, Esmaeili M, Abolhassani H, Vaeli S, Rezaei A, et al. Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. Clinical Immunology. 2017;175:124-32.
11. Talaei Z, Sheikhbahaei S, Ostadi V, Ganjalikhani Hakemi M, Meidani M, Naghshineh E, et al. Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida
Antigen. Int J Fertil Steril. 2017;11(3):134-41.
12. Afshar-Qasemloo S, Esmaeil N, Ganjalikhani-Hakemi M, Rezaei A,Yazdani R, Abbasi-Rad F. Comparison of B-Cells Differentiation to Plasmablasts at Presence of Anti-Human CD40 and Anti-Immunoglobulin M F(ab)'2 or Lipopolysaccharide and Anti-HumanCD40 Stimulators (In-Vitro). Journal of Isfahan Medical School.2017;35(427):440-6.
13. Sadri M, Ganjalikhani-Hakemi M, Akbari P, Salehi R, Rastaghi S, Ghasemi R, et al. Association between 4259 T>G and -574 G>T Polymorphisms of TIM-3 with Asthma in an Iranian Population. Iran J
Allergy Asthma Immunol. 2017;16(4):321-8.
14. Rezaeepoor M, Shapoori S, Ganjalikhani-Hakemi M, Etemadifar M, Alsahebfosoul F, Eskandari N, et al. Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients.
15. Rezaeepoor M, Shapoori S, Ganjalikhani-hakemi M, Etemadifar M, Alsahebfosoul F, Eskandari N, et al. Statistical support for Sema3A and multiple sclerosis. Gene. 2017;626:87-8.
16. Pouladian M, Ganjalikhani-Hakemi M, Alsahebfosul F, Homayouni V, Khosravi S, Etemadifar M, et al. The+ 4259A> C polymorphism of TIM-3 but not-1637C> T polymorphism of TIM-1 is associated with Multiple sclerosis in Isfahan population. Multiple sclerosis and related disorders. 2017;18:152-6.
17. Mahmoudi MB, Abed Khojasteh M, Alsahebfosoul F, Gharibdoost F, Mostafaei S, Ganjalikhani‐hakemi M, et al. Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level. Journal of cosmetic dermatology. 2017:doi:10.1111/jocd.12420.
18. Khazraei-Moradian S, Ganjalikhani-Hakemi M, Andalib A, Yazdani R, Arasteh J, Kardar GA. The Effect of Licorice Protein Fractions on Proliferation and Apoptosis of Gastrointestinal Cancer Cell Lines. Nutr Cancer. 2017;69(2):330-9.
19. Jafarinia M, Lotfi N, Ganjalikhani-hakmi M, Rezaei A. Regulatory T Cells in Colorectal Cancer. Immuno regulation. 2017;1(1):1-6.
20. Homayouni V, Khanahmad H, Ganjalikhani-Hakemi M, Behdani M,Ghasemi P, Rezaei A. Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3. Iranian Journal of Biotechnology. 2017;15(3):166-71.
21. Ganjalikhani-Hakemi M, Yazdani R, Esmaeili M, Abolhassani H, Rae W, Azizi G, et al. Role of Apoptosis in the Pathogenesis of Common Variable Immunodeficiency (CVID). Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2017;17(4):332-40.
22. Feizollahzadeh S, Kouhpayeh S, Rahimmansh I, Khanahmad H,Sabzehei F, Ganjalikhani-hakemi M, et al. The Increase in Protein and Plasmid Yields of E. coli with Optimized Concentration of Ampicillin as Selection Marker. Iranian Journal of Biotechnology. 2017;15(2):128-34.
23. Emamdoost F, Khanahmad H, Ganjalikhani-hakemi M, Doosti A. The miR-125a-3p inhibits TIM-3 expression in AML cell line HL-60 in vitro.Indian Journal of Hematology and Blood Transfusion. 2017;33(3):342-7.
24. Ansari M, Yazdani R, Sherkat R, Homayouni V, Ganjalikhani-Hakemi M, Rezaei A. Decreased Expression of B cell Maturation Antigen in Patients with Common Variable Immunodeficiency. Pediatric Allergy, Immunology, and Pulmonology. 2017;30(1):7-13.
25. Abbasirad F, Ganjalikhani-Hakemi M, Esmaeil N, Farrokhi S, Sherkat R, Yazdani R, et al. Assessment of the Expression Level of B-Cell Lymphoma 6 (BCL6) in Peripheral Blood CD38+ B Lymphocytes in Patients with Common Variable Immunodeficiency (CVID). Journal of Isfahan Medical School. 2017;35(432):629-34.
26. Yazdani R, Fatholahi M, Ganjalikhani-Hakemi M, Abolhassani H,Azizi G, Hamid KM, et al. Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency.Molecular immunology. 2016;71:1-9.
27. Soltanpour-Gharibdousti FK, Gholam Ali, Fazeli-Delshad B, Falak R,Ganjalikhani-Hakemi M, Andalib A. Bioinformatic Designing for Producing Vaccine Peptide of Human Vascular Endothelial Growth Factor (VEGF-A), and Evaluation of Polyclonal Antibodies in Mice. Journal of Isfahan Medical School. 2016;34(398):1054-9.
28. Mazrouei F, Ganjalikhani‐Hakemi M, Salehi R, Alesahebfosoul F,Etemadifar M, Pouladian M, et al. Association of TIM‐1 5383‐5397ins/del and TIM‐3‐1541C> T polymorphisms with multiple sclerosis in Isfahan population. International journal of immunogenetics. 2016;43(3):131-4.
29. Kavoosi F, Nikbakht-Dastjerdi M, Valiani A, Esfandiari E, Sanaei M,Ganjalikhani-Hakemi M. Genistein potentiates the effect of 17-beta estradiol on human hepatocellular carcinoma cell line. Advanced biomedical research. 2016;5: doi: 10.4103/2277-9175.187395.
30. Hosseini A, Ghaedi K, Tanhaei S, Ganjalikhani-Hakemi M, Teimuri S, Etemadifar M, et al. Upregulation of CD4+ T-Cell Derived MiR-223 in The Relapsing Phase of Multiple Sclerosis Patients. Cell Journal(Yakhteh). 2016;18(3):371-80.
31. Homayouni V, Ganjalikhani-hakemi M, Rezaei A, Khanahmad H, Behdani M, Kazemi Lomedasht F. Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3).Iranian Journal of Basic Medical Sciences. 2016;19:1201-8.
32. hassanzadeh MA, Eskandari N, Ganjalikhani-Hakemi M, Sherkat R. Investigating the Frequency of the Peripheral Blood B and Transitional B Cells in the Patients with Common Variable Immunodeficiency. Journal of Isfahan Medical School. 2016;33(357):1851-6.
33. Fooladinezhad H, Khanahmad H, Ganjalikhani-Hakemi M, Doosti A.Negative regulation of TIM-3 expression in AML cell line (HL-60)using miR-330-5p. British journal of biomedical science. 2016;73(3):129-33.
34. Feizollahzadeh S, Khanahmad H, Rahimmanesh I, Ganjalikhanihakemi M, Andalib A, Sanei MH, et al. Expression of biologically active murine interleukin-18 in Lactococcus lactis. FEMS microbiology letters. 2016;363(21):pii: fnw234.
35. Fazeli-Delshad B, Ganjalikhani-Hakemi M, Soltanpour-Gharibdousti F, Shayanfar N, Falak R, Kardar GA. Evaluation of the Functionality of 4T1 Cell Line in Development of Metastatic Cancer in Balb/c Mice as 21an Animal Model. Journal of Isfahan Medical School. 2016;34(396):985-90.
36. Eskandari N, hassanzadeh MA, Ganjalikhani-Hakemi M, Sherkat R, Khanahmad H, Yazdani Y. Evaluation of BAFF-R Mutations in Iranian Patients with Common Variable Immune Deficiency (CVID). ARC Journals of Immunology and Vaccines. 2016;1(1):1-8.
37. Ansari M, Ganjalikhani-Hakemi M, Sherkat R, Rezaei A, Yazdani R, Khosravi S. Evaluation of Mutation in B cell Maturation Antigen (BCMA) Gene in Patients with Common Variable Immunodeficiency (CVID). Journal of Isfahan Medical School. 2016;34(383):555-62.
38. Abed Khojasteh M, Alsahebfosoul F, Mahmoudi M, Mahmoudi MB,Mostafaei S, Ganjalikhani-hakemi M, et al. Comparison of theexpression levels of Fas and Apaf-1 genes in systemic sclerosis dermalfibroblasts. Tehran University Medical Journal TUMS Publications.2016;74(4):282-8.
39. Yazdani R, Sharifi M, Shirvan AS, Azizi G, Ganjalikhani-Hakemi M.Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol. 2015;298(1-2):66-76.
40. Shirzade H, Meshkat R, Ganjalikhani‐Hakemi M, Mosayebian A, Ghasemi R, Deress F, et al. Association analysis of− 416 G> C polymorphism of T‐cell immunoglobulin and mucin domain‐1 gene with asthma in Iran. International journal of immunogenetics. 2015;42(4):265-9.
41. Sherkat R, Ali-Hassanzadeh M, Eskandari N, Ganjalikhani-Hakemi M, Esmaeil N, Rezaei N. Clinical Features of Immunological Dysregulation in Common Variable Immunodeficiency in Iran. British Journal of Medicine and Medical Research. 2015;7(8):647-53.
42. Shajanian S, Gharagozloo M, Ganjalikhani-Hakemi M, Rafiee M. Comparing In-Vitro Effects of Two Immunosuppressive Drugs on the Expression of Foxp3 from Naïve CD4+ T Cells. Journal of Isfahan
Medical School. 2015;33(329):457-66.
43. Sadri M, Ganjalikhani-Hakemi M, Salehi R, Ghasemi R, Rastaghi S. Prevalence of TIM-3 Gene Polymorphisms in Patients with Asthma and its correlation with Serum Levels of Immunoglobulin-E of These
Patients in Isfahan, Iran. Journal of Isfahan Medical School. 2015;32(314):2193-201.
44. Pouladian M, Ganjalikhani-Hakemi M, Salehi R, AlSahebfosul F,Khosravi S, Etemadifar M, Mazrouei F. Comparing the frequency of TIM-3 polymorphism in Multiple Sclerosis patients with healthy controls. Journal of Isfahan Medical School. 2015;33(341):1066-75.
45. Naghavian R, Honardoost M, Hosseini A, Ghaedi K, Etemadifar M,Nasr Esfahani M, Ganjalikhani-Hakemi M. The possibility of miR- 20a/b & miR-93 role in differentiation of naïve CD4+ to Th17 cells in multiple sclerosis. Scientific Journal of Iranian Blood Transfusion Organization. 2015;12(1):39-45.
46. Naghavian R, Ghaedi K, Kiani-Esfahani A, Ganjalikhani-Hakemi M,Etemadifar M, Nasr-Esfahani MH. miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis. PLoS One. 2015;10(5):e0124555.
47. Mollainezhad H, Eskandari N, Pourazar A, Andalib A, Salehi M,Ganjalikhani-Hakemi M. miR-370 Expression Analysis in Breast Cancer. Journal of Isfahan Medical School. 2015;33(339):924-31.
48. Mazrouei F, Ganjalikhani-Hakemi M, Salehi R, Ale-Sahebfosoul F,Etemadifar M, Zarkesh-Esfahani H. The Frequency of TIM-3-1541C>TPolymorphisms and its Association with Multiple Sclerosis. Journal of Isfahan Medical School. 2015;33(335):739-46.
49. Haghighatfard H, Samaei N, Farazmandfar T, Ganjalikhani-HakemiM, Yamchi A, Jadidi-Niaragh F, et al. Molecular Cloning and Expression of Novel Fibroblast Growth Factor-2 Conjugated with Immunodominant Domains of Pseudomonas exotoxin. Biomedical and Pharmacology Journal. 2015;8(2):1195-200.
50. Ghatrehsamani M, Soleimani M, Moayedi-Esfahani BA, Ganjalikhani- Hakemi M, Shirzad H, Eskandari N, et al. 2, 3, 7, 8-tetrachlorodibenzop- dioxin decrease expression of aryl hydrocarbon receptor in peripheral lymphocyte of β-thalassemia major patients. Advanced biomedical research. 2015;4:doi: 10.4103/2277-9175.166.
51. Ghatrehsamani M, Soleimani M, Moayedi-Esfahani BA, Shirzad H,Ganjalikhani-Hakemi M, Mossahebimohammadi M, et al. Tumor necrosis factor-α inhibits effects of aryl hydrocarbon receptor ligands
on cell death in human lymphocytes. Advanced biomedical research. 2015;4: doi: 10.4103/2277-9175.166163.
52. Ghadiri N, Hosseini A, Ghaedi K, Emamnia NA, Ganjalikhani Hakemi M, Shirzad H, et al. Prediction of miR-34a and miR-215 impact on differentiation of naive CD4+ T cells to Th17 cells in multiple sclerosis. journal of shahrekord university of medical sciences. 2015.
53. Ebrahimi M, Kazemi T, Ganjalikhani-Hakemi M, Majidi J, Khanahmad H, Rahimmanesh I, et al. Development of a Stable Cell Line, Overexpressing Human T-cell Immunoglobulin Mucin 1. Iran J Biotechnol. 2015;13(4):25-31.
54. Nikbakht-Dastjerdi M, Kavoosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, Ganjalikhani-Hakemi M, et al. Inhibitory Effect of Genistein on PLC/PRF5 Hepatocellular Carcinoma Cell Line. Int J Prev Med. 2015;6(1):54-61.
55. Mosayebian A, Ganjalikhani Hakemi M, Meshkat R, Ghasemi R, Khanahmad H, Samadi M. Association between Interleukin-23 Receptor R381Q Gene Polymorphism and Asthma. Iran J Allergy Asthma Immunol. 2015;14(4):386-91.
56. Yazdani R, Ganjalikhani-Hakemi M, Sherkat R, Homayouni V, Farahani R. Genetic defects and the role of helper T-cells in the pathogenesis of common variable immunodeficiency. Advanced biomedical research. 2014;3(2): doi: 10.4103/2277-9175.124627.
57. Shirzad H, Meshkat R, Gangalikhani-Hakemi M, Salehi R, Ghasemi R,Hashemzadeh M, et al. Association Analysis of T-Cell Immunoglobulin and Mucin 1 Gene 5383-5397 Insertion/Deletion Polymorphism with Asthma and Total Serum Immunoglobulin E Levels in Patients with Asthma and Controls. Journal of Isfahan Medical School. 2014;32(300):1423-32.
58. Sherkat R, Yazdani R, Ganjalikhani-Hakemi M, Homayouni V, Farahani R, Hosseini M, et al. Innate lymphoid cells and cytokines of the novel subtypes of helper T cells in asthma. Asia Pacific allergy. 2014;4(4):212.
59. Yazdani R, Ganjalikhani-Hakemi M, Sherkat R, Rezaei A, Farahani R,Beiranvand B. Evaluation of IL-17 gene expression in peripheral blood and sputum of asthma patients and healthy individuals. Tehran University Medical Journal TUMS Publications. 2014;72(9):595-600.
60. Moballegh-Naseri M, Khanahmad H, Homayouni V, Ganjalikahni- Hakemi M, Salehi M, Rahim-Manesh I, et al. Producing Recombinant HEK293 T-cells with High Expression of T-cell Immunoglobulin and Mucin Domain-3 (Tim3) Protein. Journal of Isfahan Medical School. 2014;32(317):2312-23.
61. Komijany F, Dashti GR, Salamat MR, Ganjalikhani-Hakemi M, Abdar-Esfahani M, Adibi A. the Relationship of the Serum Level of Osteoprotegerin and Bone Mineral Density in Postmenopausal Women. Journal of Isfahan Medical School. 2014;32(318):2349-59.
62. Khazraei-Moradian S, Andalib A, Ganjalikhani-Hakemi M, Safari Z, Zare A, Kardar GA. The Effect of Protein Extract of Licorice Root in Proliferation of HT-29 and CT26 Cancer Cell Lines. Journal of Isfahan Medical School. 2014;32(298):1338-46.
63. Ganjalikhani-Hakemi M, Yazdani R, Sherkat R, Homayouni V, Masjedi M, Hosseini M. Evaluation of the T helper 17 cell specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency. Journal of research in medical sciences. 2014;19(Suppl 1):S30.
64. Ganjalikhani Hakemi M, Ghaedi K, Homayouni V, Andalib A,Hosseini M, Rezaei A. Positive and negative regulation of Th17 cell differentiation: evaluating the impact of RORC2. Cell Journal 2014;16(3):343-52.
65. Farahani R, Sherkat R, Ganjalikhani-Hakemi M, Eskandari N, Yazdani R. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Advanced biomedical research. 2014;3(127): doi: 10.4103/2277-9175.133249.
66. Alani B, Salehi R, Sadeghi P, Zare M, Khodagholi F, Arefian E, Ganjalikhani-Hakemi, M, et al. Silencing of Hsp90 chaperone expression protects against 6-hydroxydopamine toxicity in PC12 cells. Journal of Molecular Neuroscience. 2014;52(3):392-402.
67. Yazdani R, Ganjalikhani-Hakemi M, Sherkat R, Masjedi M, Zarkesh H, Hosseini M. Evaluation of IL-17 Gene Expression in the Peripheral Blood of Patients with Common Variable Immunodeficiency. Journal of Isfahan Medical School. 2013;31(230):358-63.
68. Ganjalikhani hakemi M, Hashemi M. siRNA delivery improvement co-formulation of different modified polymers in erythroleukemic cell line K562 Iranian Journal of Basic Medical Sciences. 2013; 16: 973-8.
69. Ganjalikhani Hakemi M, Ghaedi K, Andalib A, Homayouni V, Hosseini M, Rezaei A. RORC2 gene silencing in human Th17 cells by siRNA: design and evaluation of highly efficient siRNA. Avicenna journal of medical biotechnology. 2013;5(1):10.
70. Behfarnia P, Birang R, Pishva SS, Ghanjalikhani Hakemi M, Mitra MK. Expression Levels of Th-2 and Th-17 Characteristic Genes in Healthy Tissue Versus Periodontitis. Journal of Dentistry of Tehran University of Medical Sciences. 2013;10 (1):23-31.
71. Adibrad M, Deyhimi P, Ganjalikhani Hakemi M, Behfarnia P, Shahabuei M, Rafiee L. Signs of the presence of Th17 cells in chronic periodontal disease. Journal of periodontal research. 2012;47(4):525-31.
72. Ganjalikhani Hakemi M, Ghaedi K, Andalib A, Hosseini M, Rezaei A. Optimization of human Th17 cell differentiation in vitro: evaluating different polarizing factors. In Vitro Cellular & Developmental Biology-Animal. 2011;47(8):581.
73. Nicknam MH, Mahmoudi M, Amirzargar AA, Ganjalikhani-Hakemi M, Khosravi F, Jamshidi AR, et al. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iranian Journal of Allergy, Asthma and Immunology. 2008;7(1):19-24.
74. Nicknam M, Ganjalikhani hakemi M, Jamshidi A, Khosravi F,Amirkhani A, Narouinejad M, et al. Association between HLA-B27 antigen and ankylosing spondylitis in iranian patients. Hakim. 2005;8(1):29-34.
75. Nicknam M, Jamshidi A, Ganjalikhani Hakemi M, Khosravi F,Amirkhani A, Narouinejad M, et al. Comparison of val idity ofmicrolymphocytotoxicity and flowcytometry methods with PCR forHLA-B27 antigen typing. Medical Journal of The Islamic Republic of Iran (MJIRI). 2003;17(1):75-9.